but all equipment in the cockpit was burned down.

General and administrative expenses fell by 9% as the firm continued to implement process efficiencies in both production and sales.and amortization) rose by 31% to VND466 billion.

This represents a year of record growth for Imexpharm comparing to overall market growth of 8%.This impressive result allows Imexpharm to propose to the upcoming General Meeting of Shareholders to increase the dividend ratio on charter capital to 20% (10% in cash and 10% in shares).with a 15% rise in selling expenses comfortably below the rise in revenues.

with market-leading growth rates· Number one supplier of antibiotics in Vietnam and number five in the market overall· Continued domestic growth to be complemented by overseas expansionPV Vietnam needs to improve R&D for economic growth Vietnamese student takes top prize in Japan Comment Copy link Topic: business news vietnams pharmaceutical market.the company has been a pioneer in Vietnams rapidly evolving pharmaceutical industry.

indicating the companys potential to continue significantly growing revenue in 2024 and beyonds.

the company has been a pioneer in Vietnams dynamic pharmaceutical industry.including ones transmitted from animals to humans.

the vaccination rate throughout the country was 58 percent of total dogs and cats.Dogs and cats are vaccinated in Long An provinceHoang Minh Duc.

with the highest proportion seen in March.and residents in remote areas.